MIB-626: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 39 patientsc19early.org

MIB-626 for COVID-19

Serious outcome risk
MIB-626
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−156%
Mortality (1)−156%
RCTs (1)−156%
Late (1)−156%
00.511.5+
← MIB-626
reduces riskIncreased
risk →
c19early.org
October 2026

MIB-626 COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Pencina (DB RCT)−156%2.56 · 0.11–58.97death1/250/14
Late treatment−156%2.56 · 0.11–58.971/250/14156% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.57
All studies−156%2.56 · 0.11–58.971/250/14156% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5700.511.52+
Rotate screen for more detailsIncrease width for more details
← MIB-626
reduces riskMIB-626
increases risk →
c19early.org
October 2026

MIB-626 COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Pencina (DB RCT)−156%2.56 · 0.11–58.971/250/14
Late treatment−156%2.56 · 0.11–58.971/250/14156% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.57
All studies−156%2.56 · 0.11–58.971/250/14156% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5700.511.52+
Rotate screen for more detailsIncrease width for more details
← MIB-626
reduces riskMIB-626
increases risk →
c19early.org
October 2026

MIB-626 COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Pencina (DB RCT)−156%2.56 · 0.11–58.97death1/250/14
Late treatment−156%2.56 · 0.11–58.971/250/14156% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.57
All studies−156%2.56 · 0.11–58.971/250/14156% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5700.511.52+
Rotate screen for more detailsIncrease width for more details
← MIB-626
reduces riskMIB-626
increases risk →
c19early.org
October 2026

MIB-626 COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Pencina (DB RCT)18%0.82 · 0.29–2.27no recov.19 (n)15 (n)
Late treatment18%0.82 · 0.29–2.2719 (n)15 (n)18% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.71
All studies18%0.82 · 0.29–2.2719 (n)15 (n)18% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.7100.511.52+
Rotate screen for more detailsIncrease width for more details
← MIB-626
reduces riskMIB-626
increases risk →
c19early.org
October 2026

MIB-626 COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Pencina (DB RCT)−156%2.56 · 0.11–58.97death1/250/14
Late treatment−156%2.56 · 0.11–58.971/250/14156% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.57
All studies−156%2.56 · 0.11–58.971/250/14156% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5700.511.52+
Rotate screen for more detailsIncrease width for more details
← MIB-626
reduces riskMIB-626
increases risk →
c19early.org
October 2026

MIB-626 COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Pencina (DB RCT)−156%2.56 · 0.11–58.971/250/14
Late treatment−156%2.56 · 0.11–58.971/250/14156% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.57
All studies−156%2.56 · 0.11–58.971/250/14156% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5700.511.52+
Rotate screen for more detailsIncrease width for more details
← MIB-626
reduces riskMIB-626
increases risk →
c19early.org
October 2026

MIB-626 COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Pencina (DB RCT)−156%2.56 · 0.11–58.97death1/250/14
Late treatment−156%2.56 · 0.11–58.971/250/14156% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.57
All studies−156%2.56 · 0.11–58.971/250/14156% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5700.511.52+
Rotate screen for more detailsIncrease width for more details
← MIB-626
reduces riskMIB-626
increases risk →